Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ.
BACKGROUND
The aim of this study was to measure HrQoL during acute exacerbations of COPD using generic and disease-specific instruments, and to assess completeness, proportion with best or worst health state, sensitivity to change and discriminative ability for each instrument.


METHODS
EQ-5D, SF-12 and SGRQ were obtained from COPD patients with GOLD stage III and IV hospitalized for an acute exacerbation both at admission and discharge. To assess the instruments' properties, utility values were calculated for EQ-5D and SF-12, and a total score was derived from the SGRQ.


RESULTS
Mean utilities ranged from 0.54 (SF-12, stage IV) to 0.62 (EQ-5D, stage III) at admission, and from 0.58 (SF-12, stage IV) to 0.84 (EQ-5D, stage III) at discharge. Completeness was best for EQ-5D and SGRQ, while no utility value for the SF-12 could be calculated for more than 30%. For SGRQ subscales, the minimal score occurred in up to 11% at admission, while full health was observed for the EQ-5D at discharge in 13%. Sensitivity to change was generally good, whereas discrimination between COPD stages was low for the EQ-5D.


CONCLUSIONS
Acute exacerbations seriously impair health status and quality of life. The EQ-5D is generally suitable to measure HrQoL in exacerbations of severe COPD, although the high proportion of patients reporting full health at discharge poses a problem. The main issue with the SF-12 is the high proportion of missing values in a self-assessed setting. Properties of the SGRQ were satisfactory. However, since no utility values can be derived from this disease-specific instrument, it is not suitable for cost-utility analyses in health-economic evaluations.
Menn
Petra
P
Helmholtz Zentrum München - German Research Center for Environmental Health, Institute of Health Economics and Health Care Management, Neuherberg, Germany. petra.menn@helmholtz-muenchen.de
Weber
Norbert
N
Holle
Rolf
R
D000368:Aged; D005260:Female; D005858:Germany; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D011594:Psychometrics / Q000379:methods; D029424:Pulmonary Disease, Chronic Obstructive; D011788:Quality of Life; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
Pneumologie. 2004 Dec;58(12):837-44
15597250
Chest. 2002 Mar;121(3):688-96
11888946
Health Qual Life Outcomes. 2009 Jul 22;7:69
19624834
Biometrics. 2006 Mar;62(1):185-92
16542245
Biometrics. 2003 Dec;59(4):1089-98
14969489
Health Qual Life Outcomes. 2006 May 23;4:31
16719899
Pharmacoeconomics. 2005;23(4):345-63
15853435
Lancet. 2003 Feb 8;361(9356):449-56
12583942
Chest. 2006 Oct;130(4):1117-28
17035446
Qual Life Res. 2009 Mar;18(2):267-72
19105049
Med Care. 2004 Sep;42(9):851-9
15319610
Eur J Health Econ. 2005 Jun;6(2):124-30
19787848
Int J Clin Pract. 2007 Jul;61(7):1112-20
17577296
Lancet. 2007 Sep 1;370(9589):786-96
17765528
Dtsch Med Wochenschr. 2008 Dec;133(50):2609-14
19052996
Health Econ. 2004 Sep;13(9):873-84
15362179
Am Rev Respir Dis. 1992 Jun;145(6):1321-7
1595997
Eur J Health Econ. 2009 Feb;10(1):15-23
18327677
Biometrics. 1995 Mar;51(1):351-3
7766789
Health Policy. 1990 Dec;16(3):199-208
10109801
Health Econ. 2003 Dec;12(12):1061-7
14673814
Med Care. 1997 Nov;35(11):1095-108
9366889
Health Qual Life Outcomes. 2005 Sep 09;3:56
16153294